Sunday, July 7, 2013

Secukinumab superior to Enbrel in the treatment of Psoriasis

In a head to head Phase 3 trial comparing Novartis' Secukinumab to Enbrel in the treatment of Psoriasis, Secukinumab has demonstrated superiority. 

The FIXTURE trial (the Full year Investigative eXamination of secukinumab vs. eTanercept Using 2 dosing Regimens to determine Efficacy in psoriasis) was a randomized, double-blind, double-dummy, placebo-controlled, multicenter global study of subcutaneous secukinumab (AIN457) in moderate-to-severe plaque psoriasis involving 1,307 patients. It was designed to demonstrate efficacy after 12 weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy up to 52 weeks. Established treatment measures were used to assess the efficacy of secukinumab (AIN457) including PASI 75 (Psoriasis Area and Severity Index 75) and the Investigator's Global Assessment (IGA mod 2011), a standard tool to assess the clearing of skin after treatment.



Regulatory submissions for secukinumab (AIN457), a therapy targeting IL-17A, are on track for the second half of 2013


Enter your email address:


Delivered by FeedBurner